Author: [AUTHOR] Published on 4/1/2024 12:00:00 AM
Mayur Ladumor, PhD, Senior Scientist, Pharmacokinetics, Dynamics, Metabolism & Bioanalytics PDMB, Merck & Co., Inc., West Point, PA
What excites you about serving in your role as the Special Populations (SPO) Community Chair?
As Helen Keller once said, “Alone we can do so little; together we can do so much.” I am deeply inspired by the mission of the SPO community, which seeks to engage diverse professionals in addressing the unique challenges faced by special populations. Often, due to both ethical and logistical hurdles, clinical trials are not feasible for these groups. I am passionate about the Community's commitment to advancing clinical pharmacology for populations such as pregnant individuals, children, the elderly, and those with hepatic/renal impairment. This role gives me a platform to advocate for their needs and to ensure, at least to some degree, that these needs are recognized and addressed. The chance to collaborate with pioneers in the field, share knowledge, and drive initiatives that benefit our community genuinely excites me.
What professional accomplishment are you most proud of?
I am trained as a pharmacist, and my PhD work shaped my interest in model-informed drug development (MIDD). During my research, as I conducted rat experiments, I often contemplated alternative methods that could not only reduce the necessity for human trials but also spare animal lives.
I believe my proudest professional accomplishment is my contribution to the application of mechanistic and physiological mathematical models in predicting drug exposure in healthy as well as special populations. I have done so through multiple publications on the development of physiologically-based pharmacokinetic models for special populations such as children, pregnant individuals, and those with hepatic impairment. These modeling tools are also well-recognized by the health regulatory authorities. I do believe that adopting such approaches early in the drug discovery and development can substantially streamline the process, offering continuous support throughout the drug development lifecycle.
What is the most important leadership lesson you have learned the hard way?
The most crucial lesson I have learned both from my personal experience and through guidance from mentors and peers, is the importance of open communication and active listening. I have observed that most great leaders are also good listeners, which allows them to reflect deeply and respond thoughtfully. I also believe that everyone possesses unique insights and perspectives. As leaders, it is important to create an environment where everyone feels valued and comfortable sharing their ideas.
How do you keep focused and motivated?
For me, setting clear goals and visualizing the broader impact of my work are essential for maintaining focus. Recognizing that my research directly influences patient health care and improves therapeutic outcomes further keeps me motivated.
Mayur has been a member of ASCPT since 2020.
